Remepy Appoints Eran Harary, MD, to Propel Hybrid Drug Pipeline Forward#United_States#New_York#Remepy#Hybrid_Drugs#Eran_Harary
Remepy Appoints Eran Harary, MD, to Propel Hybrid Drug Pipeline Forward
Remepy has appointed Eran Harary, MD, as Chief Medical Officer to lead the advancement of its groundbreaking Hybrid Drug™ pipeline, particularly for Parkinson's disease.
third-news.com
September 16, 2026 at 11:39 AM
Remepy Appoints Eran Harary, MD, to Propel Hybrid Drug Pipeline Forward#United_States#New_York#Remepy#Hybrid_Drugs#Eran_Harary
Remepy Secures $36 Million Series A to Enhance Hybrid Drug Development for Parkinson's Disease#USA#New_York#Remepy#Hybrid_Drugs#Hybridopa
Remepy Secures $36 Million Series A to Enhance Hybrid Drug Development for Parkinson's Disease
Remepy has successfully raised $36 million in a Series A funding round, boosting development for Hybridopa, aimed at Parkinson's disease treatment, and expanding its Hybrid Drug pipeline.
third-news.com
August 12, 2026 at 12:37 PM
Remepy Secures $36 Million Series A to Enhance Hybrid Drug Development for Parkinson's Disease#USA#New_York#Remepy#Hybrid_Drugs#Hybridopa
New Mechanistic Evidence Enhancing Parkinson's Treatment with Hybridopa™ Revealed by Remepy#USA#New_York#Parkinson's#Hybridopa™#Hybrid_Drugs™
New Mechanistic Evidence Enhancing Parkinson's Treatment with Hybridopa™ Revealed by Remepy
Remepy's latest research reveals how its Hybrid Drug, Hybridopa™, improves Parkinson's patients' brain connectivity leading to better clinical outcomes. Discover the science!
third-news.com
July 1, 2026 at 11:16 AM
New Mechanistic Evidence Enhancing Parkinson's Treatment with Hybridopa™ Revealed by Remepy#USA#New_York#Parkinson's#Hybridopa™#Hybrid_Drugs™
Remepy and Merck KGaA Collaborate to Enhance Hybrid Drug Development Across Therapeutic Areas#USA#New_York#Remepy#Merk_KGaA#Hybrid_Drugs
Remepy and Merck KGaA Collaborate to Enhance Hybrid Drug Development Across Therapeutic Areas
Remepy announces a groundbreaking partnership with Merck KGaA to advance the research and development of Hybrid Drugs, merging pharmaceuticals with digital therapies.
third-news.com
April 28, 2026 at 11:16 AM
Remepy and Merck KGaA Collaborate to Enhance Hybrid Drug Development Across Therapeutic Areas#USA#New_York#Remepy#Merk_KGaA#Hybrid_Drugs